July 22, 2018 – The American Food and Drug Administration (FDA) just approved Ivosidenib (Tibsovo) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) who have a specific genetic mutation in the IDH1 gene.  It is …

Ivosidenib (Tibsovo) for AML-patients with IDH1-mutations Read more »

March 21, 2014 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting a marketing authorisation for Vynfinit (vintafolide) for the treatment of women with a subtype of platinum-resistant ovarian cancer for which there …

EMA recommends approval of Vintafolide [Vynfinit] as a new treatment for platinum-resistant ovarian cancer together with companion diagnostic. Read more »